Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 150

Sort by

Sort Order Select

Journal Articles

Targeting Epigenetic–Metabolic crosstalk in CML via butyrate-induced HDAC inhibition

Rita Vacca, Alice Danzero, Daniela Cilloni, Alessandro Ferrando, Valentina Bonuomo, Barbara Pergolizzi, Simone Rocco, afshin bagherzadehsa, Valentina Schiavo, Antonio Frolli, Selene Grano, Cristina Panuzzo, Giuseppe Saglio, Carmen Fava

Blood (2025) 146 (Supplement 1): 6810.

https://doi.org/10.1182/blood-2025-6810

Published: 2025

Journal Articles

Different kinetic behavior of molecular reduction by BCR::ABL1 transcript types in frontline treatment of chronic myeloid leukemia patients: A GIMEMA labnet CML network database survey.

Blood (2025) 146 (Supplement 1): 3755.

https://doi.org/10.1182/blood-2025-3755

Published: 2025

Journal Articles

Venetoclax and decitabine in myeloproliferative neoplasm-blast Phase (MPN-BP): Results of enable, a gimema and airc-mynerva multicenter, Phase 2 trial

Blood (2025) 146 (Supplement 1): 1025.

https://doi.org/10.1182/blood-2025-1025

Published: 2025

Journal Articles

Real world outcomes in 355 patients with Acute Myeloid Leukemia arising from chronic myelomonocytic leukemia: A multinational retrospective study

Laura Cicconi, Jad Othman, Alessandra Spagnoli, Enrico Attardi, Eleonora De Bellis, Pilar Lloret Madrid, Tamara Castaño, Juan Miguel Bergua Burgues, Arianna Savi, Ida Carmosino, Roberta Mazzarella, Armando Mena Duran, Mar Tormo, Susana Vives, Emília Cortesão, Fernanda Trigo, Mercedes Colorado, Lorenzo Algarra, Olga Salamero, José Antonio Pérez-Simón, Esther Perez, ANA Yurena Oliva Hernandez, Teresa Bernal Del Castillo, Pilar Martinez Sanchez, Claudia Lucia Scossa Melo, Cristina Gil, Marta Valero Núñez, Luis Felipe Casado Montero, Teresa Olave, Maria Vidriales Vicente, Carla Amigo, Irene Navarro Vicente, Cristian Escolano Escobar, Pilar Herrera Puente, Kenny Galvez, Rosalia Riaza Grau, Annalina Piccioni, Davide Facchinelli, Enrico Santinelli, Raffaele Palmieri, Giovanni Luzi, Monica Piedimonte, Sabrina Mariani, Luana Fianchi, Carmela Gurrieri, Ilaria Tanasi, Davide Lanzarotto, Fabio Guolo, Salvatore Perrone, Elisabetta Todisco, Anjum Khan, Victoria Campbell, Maria Teresa Voso, Daniela Cilloni, Adriano Venditti, Roberto Latagliata, Richard Dillon, Massimo Breccia, Luca Maurillo, Susanna Fenu, Alessandro Pulsoni, Pau Montesinos

Blood (2025) 146 (Supplement 1): 3437.

https://doi.org/10.1182/blood-2025-3437

Published: 2025

Journal Articles

Real-world validation of ELN2024 and BEAT-AML2024 risk-stratification in patients with Acute Myeloid Leukemia unfit for intensive chemotherapy in a multicenter italian cohort.

Arianna Savi, Giovanni Fornari, Johanna Umurungi, Beatrice Sani, Alessandro Cignetti, Ernesta Audisio, Elisabetta Todisco, Enrico Santinelli, Marianna Norata, Cristina Papayannidis, Raffaele Palmieri, Adriano Venditti, Monia Marchetti, Daniela Cilloni

Blood (2025) 146 (Supplement 1): 1624.

https://doi.org/10.1182/blood-2025-1624

Published: 2025

Journal Articles

Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy

Blood (2024) 144 (Supplement 1): 3162.

https://doi.org/10.1182/blood-2024-201493

Published: 2024

Journal Articles

Molecular Outcome of Chronic Myeloid Leukemia Affected Patients Not in Deep Molecular Response: The “Others” from the Gimema Labnet Network

Blood (2024) 144 (Supplement 1): 992.

https://doi.org/10.1182/blood-2024-210201

Published: 2024

Journal Articles

Myelodysplastic Neoplasms Patients' and Caregivers' Unmet Needs and Their Impact on Their Quality of Life and Symptoms

Blood (2024) 144 (Supplement 1): 3800.

https://doi.org/10.1182/blood-2024-210768

Published: 2024

Journal Articles

Cytopenias and Failure to Use Innovative Therapy Are Main Drivers of Worse Outcome after Discontinuation of Ruxolitinib in Myelofibrosis

Blood (2024) 144 (Supplement 1): 6664.

https://doi.org/10.1182/blood-2024-199961

Published: 2024

Journal Articles

First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis

Blood (2024) 143 (14): 1399–1413.

https://doi.org/10.1182/blood.2023021349

Published: 2024

Includes: Supplemental data

Journal Articles

Safety and Efficacy of New Drugs Combinations in Newly Diagnosed Multiple Myeloma with Renal Failure at Onset: A Retrospective Multicentric Study

Antonio Frolli, Claudio Cerchione, Riccardo Staiano, Tommasina Guglielmelli, Davide Nappi, Agnese Mattei, Silvia Marini, Daniela Cilloni, Guido Eugenio Parvis

Blood (2023) 142 (Supplement 1): 6656.

https://doi.org/10.1182/blood-2023-190212

Published: 2023

Journal Articles

First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis

Blood (2023) 142 (Supplement 1): 4135.

https://doi.org/10.1182/blood-2023-189094

Published: 2023

Journal Articles

A Radiation-Free Approach Based on the Whole-Body-MRI Has Shown a High Level of Accuracy in the Follow up of Lymphoma Patients. a Single Center Retrospective Study

Antonio Frolli, Silvia Varvello, Annalisa Balbo Mussetto, Daniela Gottardi, Martina Bullo, Silvia Marini, Giuseppe Saglio, Stefano Cirillo, Daniela Cilloni, Guido Eugenio Parvis

Blood (2022) 140 (Supplement 1): 9317.

https://doi.org/10.1182/blood-2022-168519

Published: 2022

Journal Articles

Patient Specific Droplet Digital PCR Targeting FLT3-ITD Allows to Detect Small Clones in Acute Leukemias at Diagnosis and during Follow-up

Daniela Cilloni, Johanna Umurungi, Valentina Bonuomo, Federico Itri, Cristina Rotolo, Silvia Marini, Monia Lunghi, Andrea Castelli, Carmen Fava, Giuseppe Saglio, Alessandro Cignetti, Jessica Petiti

Blood (2022) 140 (Supplement 1): 11827–11828.

https://doi.org/10.1182/blood-2022-167017

Published: 2022

Journal Articles

Real-World Management of Advanced Systemic Mastocytosis Treated with Midostaurin: Analysis of Patients Who Completed 12 Months of Follow-up from an Italian Observational Study (OVIDIO)

Blood (2022) 140 (Supplement 1): 9685–9687.

https://doi.org/10.1182/blood-2022-156371

Published: 2022

Journal Articles

Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)

Luca Lanino, Prassede Salutari, Alessandra Perego, Bruno Fattizzo, Marta Riva, Marta Ubezio, Pellegrino Musto, Daniela Cilloni, Esther Natalie Oliva, Maria Teresa Voso, Anna Maria Pelizzari, Antonella Poloni, Isabella Capodanno, Chiara Elena, Claudio Fozza, Fabrizio Pane, Massimo Breccia, Marco De Gobbi, Francesco Di Bassiano, Daniela Barraco, Elena Crisà, Dario Ferrero, Chiara Frairia, Antonella Vaccarino, Davide Griguolo, Stefania Paolini, Martina Quintini, Mariarosaria Sessa, Mauro Turrini, Monica Bocchia, Nicola Di Renzo, Elisa Diral, Cristina Foli, Alfredo Molteni, Ubaldo Occhini, Giulia Rivoli, Carmine Selleri, Roberto Bono, Anna Calvisi, Andrea Castelli, Eros Di Bona, Ambra Di Veroli, Luana Fianchi, Sara Galimberti, Daniele Grimaldi, Monia Marchetti, Marianna Norata, Alessandro Rambaldi, Ilaria Tanasi, Patrizia Tosi, Ilaria Naldi, Valeria Santini, Matteo G. Della Porta

Blood (2022) 140 (Supplement 1): 6945–6948.

https://doi.org/10.1182/blood-2022-164559

Published: 2022

Journal Articles

Mylox-1: An Open-Label, Phase IIa Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral LOXL2 Inhibitor, GB2064, in Myelofibrosis

Srdan Verstovsek, John Mascarenhas, Raajit K Rampal, Daniela Cilloni, Claire Harrison, Brian Jacoby, Robert J. Slack, Vassilios Aslanis, Bobby Singh, Bertil Lindmark

Blood (2022) 140 (Supplement 1): 3868–3870.

https://doi.org/10.1182/blood-2022-167496

Published: 2022

Journal Articles

Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)

Blood (2022) 140 (Supplement 1): 9688–9690.

https://doi.org/10.1182/blood-2022-157914

Published: 2022

Journal Articles

Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 2351.

https://doi.org/10.1182/blood-2021-144912

Published: 2021

Journal Articles

Peripheral Blasts Are Associated with Response to Ruxolitinib and Outcome in Patients with Chronic-Phase Myelofibrosis

Blood (2021) 138 (Supplement 1): 3624.

https://doi.org/10.1182/blood-2021-152420

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Targeting Epigenetic–Metabolic crosstalk in CML via butyrate-induced HDAC inhibition

Different kinetic behavior of molecular reduction by BCR::ABL1 transcript types in frontline treatment of chronic myeloid leukemia patients: A GIMEMA labnet CML network database survey.

Venetoclax and decitabine in myeloproliferative neoplasm-blast Phase (MPN-BP): Results of enable, a gimema and airc-mynerva multicenter, Phase 2 trial

Real world outcomes in 355 patients with Acute Myeloid Leukemia arising from chronic myelomonocytic leukemia: A multinational retrospective study

Real-world validation of ELN2024 and BEAT-AML2024 risk-stratification in patients with Acute Myeloid Leukemia unfit for intensive chemotherapy in a multicenter italian cohort.

Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy

Molecular Outcome of Chronic Myeloid Leukemia Affected Patients Not in Deep Molecular Response: The “Others” from the Gimema Labnet Network

Myelodysplastic Neoplasms Patients' and Caregivers' Unmet Needs and Their Impact on Their Quality of Life and Symptoms

Cytopenias and Failure to Use Innovative Therapy Are Main Drivers of Worse Outcome after Discontinuation of Ruxolitinib in Myelofibrosis

First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis

Safety and Efficacy of New Drugs Combinations in Newly Diagnosed Multiple Myeloma with Renal Failure at Onset: A Retrospective Multicentric Study

First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis

A Radiation-Free Approach Based on the Whole-Body-MRI Has Shown a High Level of Accuracy in the Follow up of Lymphoma Patients. a Single Center Retrospective Study

Patient Specific Droplet Digital PCR Targeting FLT3-ITD Allows to Detect Small Clones in Acute Leukemias at Diagnosis and during Follow-up

Real-World Management of Advanced Systemic Mastocytosis Treated with Midostaurin: Analysis of Patients Who Completed 12 Months of Follow-up from an Italian Observational Study (OVIDIO)

Mylox-1: An Open-Label, Phase IIa Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral LOXL2 Inhibitor, GB2064, in Myelofibrosis

Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)

Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia

Peripheral Blasts Are Associated with Response to Ruxolitinib and Outcome in Patients with Chronic-Phase Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only